Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) Stock Short Interest Climbs 96.3%

Ascentage Pharma Group International – Unsponsored ADR (NASDAQ:AAPG) saw a large increase in short interest in the month of October. As of October 15th, there was short interest totaling 18,161 shares, an increase of 96.3% from the September 30th total of 9,250 shares. Approximately 0.0% of the company’s stock are sold short. Based on an average daily trading volume, of 7,124 shares, the short-interest ratio is presently 2.5 days.

Ascentage Pharma Group International Trading Down 6.2%

Shares of AAPG stock opened at $13.56 on Tuesday. The company has a debt-to-equity ratio of 1.09, a quick ratio of 1.18 and a current ratio of 1.22. The company has a 50 day moving average of $15.78 and a 200-day moving average of $20.13. Ascentage Pharma Group International has a 12-month low of $13.46 and a 12-month high of $34.50.

Ascentage Pharma Group International (NASDAQ:AAPG) last posted its quarterly earnings results on Wednesday, August 19th. The company reported ($0.65) EPS for the quarter. The firm had revenue of $22.24 million during the quarter. As a group, analysts predict that Ascentage Pharma Group International will post -2.43 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on AAPG. Citizens Jmp initiated coverage on Ascentage Pharma Group International in a research report on Tuesday, October 13th. They issued a “market outperform” rating and a $35.00 target price for the company. Citigroup initiated coverage on Ascentage Pharma Group International in a research report on Wednesday, October 14th. They set a “buy” rating and a $46.00 target price on the stock. BTIG Research reiterated a “buy” rating and issued a $48.00 target price on shares of Ascentage Pharma Group International in a report on Friday, August 21st. William Blair started coverage on shares of Ascentage Pharma Group International in a research report on Friday, October 16th. They issued an “outperform” rating for the company. Finally, JPMorgan Chase & Co. decreased their price target on shares of Ascentage Pharma Group International from $46.00 to $33.00 and set an “overweight” rating for the company in a research note on Thursday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating and twelve have given a Buy rating to the company. According to data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $43.90.

Ascentage Pharma Group International Company Profile

Ascentage Pharma Group International is a commercial-stage biopharmaceutical company focused on developing and commercializing treatments for cancer and other serious diseases.